Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>Resources>Application Notes>This Application Note
  Application Notes
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Development in Preventing Macular Degeneration
Following macular degeneration insight, promising drugs to prevent vision loss have been identified.
Improving Tumour Therapy with Nanoparticles
UHN nanoparticle called PEARLs is a promising utilisation of photo-thermal therapy for cancer treatment.
New Antidepressant Treatment Discovered
Scientists have demonstrated how gene therapy could lead to new treatments for depression.
Cellular Origin of Skin Cancer Identified
Scientists have identified ‘cell of origin’ in the most common form of skin cancer, and followed the process that leads to tumour growth.
Enhancing Drug Safety with a Web-Based Data Tool
Online and open-access tool allows anyone to find, combine and analyse FDA drug information.
Scroll Up
Scroll Down

Performing ADCC Reporter Bioassay with an Environmentally Controlled Microplate Reader
Bookmark and Share

Tecan Group Ltd.

Bioassays designed to measure antibody-dependent cell-mediated cytotoxicity (ADCC) are particularly useful when looking to understand and characterize mechanism of action, and to quantify biologic potency and stability of target compounds during discovery and development.

However, the labor and skill required to isolate primary natural killer cells for ADCC or to maintain alternative cell lines in culture with any level of reproducibility remains problematic, with high costs in consumable reagents and in purchasing and maintaining basic equipment.

Promega has developed reporter bioassays that use activation of gene transcription through NFAT (nuclear factor of activated T-cells) as an earlier measure of ADCC. The bioassays use frozen, thaw-and-use effector and target cells and eliminates the need for cell culture maintenance. The use of frozen cells also decreases assay variability. 

The ADCC Reporter Bioassay requires six-hour incubation with cells and antibody for optimal NFAT activation and luciferase expression to occur.The Tecan Infinite® 200 PRO, equipped with an external module that enables simultaneous adjustment of CO2 and O2, provides an alternative method enabling scientists without access to a cell culture facility to easily perform the bioluminescent reporter bioassay.

Further Information


SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!